Primecap Management Co. CA Has $12.83 Million Position in FibroGen, Inc. (NASDAQ:FGEN)

Primecap Management Co. CA trimmed its holdings in FibroGen, Inc. (NASDAQ:FGENFree Report) by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,471,928 shares of the biopharmaceutical company’s stock after selling 253,040 shares during the quarter. Primecap Management Co. CA owned about 14.72% of FibroGen worth $12,826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Assenagon Asset Management S.A. lifted its stake in FibroGen by 49.7% in the third quarter. Assenagon Asset Management S.A. now owns 2,226,857 shares of the biopharmaceutical company’s stock valued at $1,922,000 after buying an additional 739,166 shares during the period. Public Employees Retirement System of Ohio lifted its position in shares of FibroGen by 1,472.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 176,593 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 165,364 shares during the period. Armistice Capital LLC boosted its stake in FibroGen by 81.2% during the third quarter. Armistice Capital LLC now owns 7,892,000 shares of the biopharmaceutical company’s stock worth $6,810,000 after acquiring an additional 3,536,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in FibroGen in the third quarter worth $94,000. Finally, Acadian Asset Management LLC bought a new stake in FibroGen in the third quarter valued at $1,391,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Stock Performance

Shares of FGEN stock traded up $0.02 on Friday, hitting $1.30. The stock had a trading volume of 1,038,173 shares, compared to its average volume of 3,150,949. The business has a 50 day moving average of $1.52 and a 200 day moving average of $1.30. FibroGen, Inc. has a 12-month low of $0.33 and a 12-month high of $19.47.

FibroGen (NASDAQ:FGENGet Free Report) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The business had revenue of $27.14 million for the quarter, compared to analysts’ expectations of $40.00 million. Equities research analysts forecast that FibroGen, Inc. will post -1.05 EPS for the current fiscal year.

Insider Activity at FibroGen

In other FibroGen news, CEO Thane Wettig acquired 50,000 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were acquired at an average price of $1.91 per share, with a total value of $95,500.00. Following the completion of the transaction, the chief executive officer now owns 470,178 shares in the company, valued at $898,039.98. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $17.00.

Read Our Latest Report on FGEN

FibroGen Profile

(Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Further Reading

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.